Trial Profile
A phase 2 study of GW572016 [lapatinib] for brain metastases in patients with HER2-positive breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
- Focus Biomarker; Therapeutic Use
- 05 Sep 2005 New trial record.